Topical composition comprising a film-forming polymer for delivering an active ingredient to skin

a technology of film-forming polymer and active ingredient, which is applied in the direction of drug compositions, aerosol delivery, immunological disorders, etc., can solve the problems of minor release of active ingredient incorporated in the composition, and the drawback of the film-forming composition disclosed in the literatur

Inactive Publication Date: 2015-07-16
LEO PHARMA AS
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]In the course of research leading to the invention, it was surprisingly found that the oily release-enhancing agent forms oil droplets in the film upon evaporation of the solvent (cf. Example 8 and 9 showing results of atomic force microscopy (AFM) measurements of film-forming compositions disclosed herein). Without being limited to any particular theory, it is assumed that the increased release obtained from film-forming compositions comprising an oily release-enhancing agent may be the result of diffusion of the active ingredient from the matrix of film-forming polymer and plasticizer into the oil droplets from which the active ingredient is released resulting in increased and continuous release from the film-forming composition. Furthermore, the oily release-enhancing agent may act as an emollient to improve hydration of the skin and control transepidermal water loss, thus reinforcing the occlusive effect of the film-forming polymer.

Problems solved by technology

Film-forming compositions disclosed in the literature suffer from the drawback that only a minor proportion of the active ingredient incorporated therein is released from the composition.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Topical composition comprising a film-forming polymer for delivering an active ingredient to skin
  • Topical composition comprising a film-forming polymer for delivering an active ingredient to skin
  • Topical composition comprising a film-forming polymer for delivering an active ingredient to skin

Examples

Experimental program
Comparison scheme
Effect test

embodiments

[0039]In the present composition, the film-forming polymer may be selected from the group consisting of cellulose derivatives, acrylic polymers, acrylic copolymers, methacrylate polymers, methacrylate copolymers, polyurethanes, polyvinylalcohol or a derivative thereof such as polyvinylacetate, silicone polymers and silicone copolymers, and copolymers thereof.

[0040]When the film-forming polymer is a cellulose derivative, it may be selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose.

[0041]When the film-forming polymer is an acrylic polymer, it may be selected from the group consisting of methyl methacrylate and butyl methacrylate copolymer, ethyl acrylate and methyl methacrylate copolymer, acrylate and ammonium methacrylate copolymer type A and type B, and acrylates / octylacrylamide copolymer.

[0042]The film-forming polymer may suitably be present in an amount of 5-20% w / w such as 10-15% ...

example 1

Compositions

[0073]Reference compositions were prepared including the following ingredients.

PlasticizerOilSolventPolymerTECTBCDBSPEGMCTEthanolKlucel LF 5%XXXXXXEudragit E 15%XXEudragit RS 15%XXXXXDermacryl 79 10%XXXDermacryl 79 + KlucelXXLFTEC: triethyl citrateTBC: tributyl citrateDBS: dibutyl sebacatePEG: polyehtylene glycol 400MCT: medium chain triglycerides

[0074]The content of plasticizer and / or oil in the compositions was 20% by weight of the dry film-forming polymer. In addition, 1.2% by weight of betamethasone valerate (1% by weight betamethasone) was added to the compositions.

[0075]To prepare the compositions, BMV, plasticizer or oily release-enhancing agent (MCT) were dissolved in the solvent by stirring for 1-2 hours. The film-forming polymer was added slowly with stirring, and the resulting mixture was stirred overnight to complete the dissolution of the polymer.

example 2

Compositions

[0076]

Ingredients (mg / g)01A02A03A04ABetamethasone diproprionate12.8612.8612.8612.86Acrylates / octylacrylamide100100100100copolymer (Dermacryl 79)PPG-11 stearyl ether (Arlamol E)202020Polysorbate 8022Tributyl citrate20Ethanol, anhydrous887.14867.14865.14845.14

[0077]Composition 04A is a composition according to the invention, while compositions 01A, 02A and 03A are reference compositions.

[0078]To prepare the compositions, BDP, plasticizer, oily release-enhancing agent (Arlamol E) (as appropriate) and polysorbate 80 (as appropriate) were dissolved in the solvent by stirring for 1-2 hours. The film-forming polymer was added slowly with stirring, and the resulting mixture was stirred overnight to complete the dissolution of the polymer.

Compositions According to the Invention

[0079]

Ingredients (mg / g)05A06A06PBetamethasone valerate12.1412.14Eudragit RS PO150150150Medium chain triglyceride306060Tributyl citrate303030Ethanol, anhydrous777.9747.9760

[0080]To prepare the compositions,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

A film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a volatile solvent, the composition further comprising a film-forming polymer, a plasticizer and an oily release-enhancing agent. The composition is capable of forming, after application on skin and evaporation of the solvent, a continuous phase comprising the film-forming polymer and the plasticizer and a dispersed phase comprising droplets of the oily release-enhancing agent.

Description

FIELD OF INVENTION[0001]The present invention relates to a pharmaceutical composition for application on skin and containing a film-forming polymer and at least one active ingredient, the composition forming a thin and transparent two-phase film on the skin on evaporation of a solvent.BACKGROUND OF THE INVENTION[0002]Human skin, in particular the outer layer, the stratum corneum, provides an effective barrier against penetration of microbial pathogens and toxic chemicals. While this property of skin is generally beneficial, it complicates the dermal administration of pharmaceuticals in that a large quantity, if not most, of an active ingredient applied on the skin of a patient suffering from a dermal disease may not penetrate into the viable layers of the skin where it exerts its activity. To ensure an adequate penetration of the active ingredient into the dermis and epidermis, it is generally preferred to include the active ingredient in a dissolved state, typically in the presence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/32A61K47/22A61K47/10A61K31/573A61K47/14
CPCA61K47/32A61K31/573A61K47/22A61K47/10A61K47/14A61K9/0014A61K9/7015A61P17/00A61P17/04A61P17/06A61P17/08A61P17/12A61P29/00A61P37/00A61P37/06A61P37/08A61K9/12A61K47/38A61K9/124A61K47/06A61K47/08A61K47/44B65D83/752A61K47/26
Inventor PETERSSON, KARSTENFREDERIKSEN, KITOMKVIST, DIANAJANSSON, JORGEN
Owner LEO PHARMA AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products